⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1639159 | 0.74 | MAOA (0.48) | — | |
| SCHEMBL1852788 | 0.73 | — | — | |
| SCHEMBL967362 | 0.73 | — | — | |
| SCHEMBL130271 | 0.73 | — | — | |
| SCHEMBL11456454 | 0.73 | — | — | |
| SCHEMBL29785641 | 0.72 | MAOA (0.77) | — | |
| SCHEMBL2470956 | 0.72 | MAOA (0.77) | — | |
| SCHEMBL275526 | 0.72 | MAOA (0.77) | — | |
| SCHEMBL718626 | 0.72 | ADRA2A (0.56) | — | |
| SCHEMBL1851034 | 0.71 | ADRA2A (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173647-B2 | PI 3-kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2012-05-08 | — | — | US | claimed |
| EP-2118087-B1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-03-28 | — | — | EP | claimed |
| US-20100048547-A1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2010-02-25 | — | — | US | claimed |
| EP-2118087-A1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | Novartis Ag (CH) | 2009-11-18 | — | — | EP | claimed |
| WO-2008098058-A1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2008-08-14 | — | — | WO | claimed |
| US-8242116-B2 | Fused thiazole derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2012-08-14 | — | — | US | disclosed |
| US-8173647-B2 | PI 3-kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2012-05-08 | — | — | US | disclosed |
| US-8168634-B2 | Thiazole derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2012-05-01 | — | — | US | disclosed |
| EP-2118087-B1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-03-28 | — | — | EP | disclosed |
| EP-2035436-B1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2011-05-25 | — | — | EP | disclosed |
| US-20100298310-A1 | Thiazole Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2010-11-25 | — | — | US | disclosed |
| US-20100137302-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2010-06-03 | — | — | US | disclosed |
| WO-2009071895-A1 | FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009071890-A1 | TRICYCLIC KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2009-06-11 | — | — | WO | disclosed |
| EP-2035436-A1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma S.A. (BE) | 2009-03-18 | — | — | EP | disclosed |
| WO-2008098058-A1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008047109-A1 | THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2008-04-24 | — | — | WO | disclosed |
| WO-2008001076-A1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2008-01-03 | — | — | WO | disclosed |
| US-7087758-B2 | Quinoline inhibitors of hyaki and hyak3 kinases | SMITHKLINE BEECHAM CORPORATION (US) | 2006-08-08 | — | — | US | disclosed |
| US-20050043352-A1 | Quinoline inhibitors of hyaki and hyak3 kinases | SMITHKLINE BEECHAM CORPORATION | 2005-02-24 | — | — | US | disclosed |